Patents by Inventor Chu-Biao Xue

Chu-Biao Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide
    Publication number: 20060111404
    Abstract: The present invention pertains to bis(methanesulfonic acid), bis(ethanesulfonic acid), and camphoric acid salts of chemokine receptor inhibitor N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]-pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)-benzamide, methods of preparing the same, and methods of using the same.
    Type: Application
    Filed: November 21, 2005
    Publication date: May 25, 2006
    Inventors: Chu-Biao Xue, Brian Metcalf, Hui-Yin Li, Hao Feng, Joseph Glenn
  • Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 7015217
    Abstract: The present application describes novel cyclic sulfone derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof. In formula I, A is selected from —COR5, —CO2H, —CO2R6, —C(O)NHOH, —C(O)NHOR5, —C(O)NHOR6, —NHRa, —N(OH)COR5, —N(OH)CHO, —SH, —CH2SH, —S(O)(?NH)Ra, —S(?NH)2Ra, —SC(O)Ra, —PO(OH)2, and —PO(OH)NHRa; B is a thiomorpholine ring; X is absent or is CR3R4; and Ua, Xa, Ya, Za, R1, R2, Rb, and q are defined in the present specification.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: March 21, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, Chu-Biao Xue
  • 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
    Publication number: 20060020133
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Application
    Filed: June 27, 2005
    Publication date: January 26, 2006
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng Cao, Brian Metcalf
  • Cyclic ?-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-?
    Patent number: 6984648
    Abstract: The present application describes novel cyclic ?-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-? inhibitors.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Jr., Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
    Publication number: 20060004018
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Application
    Filed: June 27, 2005
    Publication date: January 5, 2006
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng. Cao, Brian Metcalf
  • 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors
    Publication number: 20050267146
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Application
    Filed: May 10, 2005
    Publication date: December 1, 2005
    Inventors: Chu-Biao Xue, Changsheng Zheng, Ganfeng Cao, Hao Feng, Michael Xia, Rajan Anand, Joseph Glenn, Brian Metcalf
  • Piperazinylpiperidine derivatives as chemokine receptor antagonists
    Publication number: 20050261310
    Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
    Type: Application
    Filed: April 12, 2005
    Publication date: November 24, 2005
    Inventors: Chu-Biao Xue, Ganfeng Cao, Taisheng Huang, Lihua Chen, Ke Zhang, Anlai Wang, David Meloni, Rajan Anand, Joseph Glenn, Brian Metcalf
  • 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
    Publication number: 20050192302
    Abstract: The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
    Type: Application
    Filed: December 16, 2004
    Publication date: September 1, 2005
    Inventors: Chu-Biao Xue, Brian Metcalf, Amy Han, Darius Robinson, Changsheng Zheng, Anlai Wang, Yingxin Zhang
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20050171096
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Application
    Filed: March 30, 2005
    Publication date: August 4, 2005
    Inventors: James Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 6906053
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: June 14, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 6890915
    Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: May 10, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Cyclic hydroxamic acid as metalloproteinase inhibitors
    Patent number: 6858626
    Abstract: The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: February 22, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Chu-Biao Xue, Carl P. Decicco, Xiaohua He
  • Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
    Publication number: 20040254231
    Abstract: The present invention provides compounds of Formula (I): 1
    Type: Application
    Filed: June 2, 2004
    Publication date: December 16, 2004
    Inventors: Jingwu Duan, Chu-Biao Xue, James Sheppeck, Bin Jiang, Lihua Chen
  • 1,1-disubstituted cyclic inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6825215
    Abstract: The present application describes novel 1,1-disubsituted cyclic derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-8 membered non-aromatic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, NR2, S, S(O), and S(O)2 and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF-&agr; inhibitors.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: November 30, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Xiao-Tao Chen, Chu-Biao Xue
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20040209874
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: May 12, 2004
    Publication date: October 21, 2004
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20040162426
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: February 13, 2004
    Publication date: August 19, 2004
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
    Publication number: 20040122005
    Abstract: The present application describes novel isoxazoline of formula I or II: 1
    Type: Application
    Filed: October 30, 2003
    Publication date: June 24, 2004
    Inventors: Chu-Biao Xue, Thomas P. Maduskuie, Stephen E. Mercer
  • Cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6743807
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 1, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco, Zhonghui Lu, Thomas P. Maduskuie, Jr., Chu-Biao Xue
  • Amide derivatives as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase
    Patent number: 6689771
    Abstract: The present application describes novel amides and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: February 10, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Carl P. DeCicco, David J. Nelson, Chu-Biao Xue
  • 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
    Patent number: 6642255
    Abstract: The present application describes novel 1,2-disubsituted cyclic derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-8 membered non-aromatic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, NR2, and S(O)p and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF-&agr; inhibitors.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: November 4, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Chu-Biao Xue, Carl Decicco, Xiaohua He